{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:20:22Z","timestamp":1785410422325,"version":"3.56.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"am","delay-in-days":368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.vaccine.2021.04.014","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T04:20:39Z","timestamp":1619151639000},"page":"2843-2849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Construction and evaluation of a pertactin-deficient live attenuated pertussis vaccine candidate BPZE1 derivative"],"prefix":"10.1016","volume":"39","author":[{"given":"Luis","family":"Solans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0570-4413","authenticated-orcid":false,"given":"Anne-Sophie","family":"Debrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8626-8109","authenticated-orcid":false,"given":"Lo\u00efc","family":"Coutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Locht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.04.014_b0005","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S1473-3099(17)30390-0","article-title":"An update of the global burden of pertussis in children younger than 5 years: a modelling study","volume":"17","author":"Yeung","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.014_b0010","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1128\/CMR.18.2.326-382.2005","article-title":"Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies","volume":"18","author":"Mattoo","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2021.04.014_b0015","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1016\/j.vaccine.2017.11.055","article-title":"Will we have new pertussis vaccines?","volume":"36","author":"Locht","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.014_b0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJM199602083340602","article-title":"A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine","volume":"334","author":"Gustafsson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.04.014_b0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJM199602083340601","article-title":"A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis","volume":"334","author":"Greco","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.04.014_b0030","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/infdis\/jit491","article-title":"Pertussis resurgence: perspectives from the working group meeting on pertussis on the causes, possible paths forward, and gaps in our knowledge","volume":"209","author":"Burns","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.014_b0035","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/cid\/ciz842","article-title":"Toward a controlled human infection model of pertussis","volume":"71","author":"Merkel","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.014_b0040","article-title":"Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough","author":"Mielcarek","year":"2006265","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2021.04.014_b0045","doi-asserted-by":"crossref","first-page":"7047","DOI":"10.1016\/j.vaccine.2010.08.017","article-title":"Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1","volume":"28","author":"Feunou","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.014_b0050","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/s41385-018-0073-9","article-title":"IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine","volume":"11","author":"Solans","year":"2018","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2021.04.014_b0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/infdis\/jix254","article-title":"Live attenuated pertussis vaccine BPZE1 protects baboons against Bordetella pertussis disease and infection","volume":"216","author":"Locht","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.014_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083449","article-title":"A phase I clinical study of a live attenuated Bordetella pertussis vaccine\u2013BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers","volume":"9","author":"Thorstensson","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.04.014_b0065","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1473-3099(20)30274-7","article-title":"Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study","volume":"20","author":"Jahnmatz","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.014_b0070","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1172\/JCI135020","article-title":"Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans","volume":"130","author":"Lin","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2021.04.014_b0075","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03942406?term=BPZE1&draw=2&rank=1"},{"key":"10.1016\/j.vaccine.2021.04.014_b0080","first-page":"159","article-title":"A natural pertactin deficient strain of Bordetella pertussis shows improved entry in human monocyte-derived dendritic cells","volume":"32","author":"Stefanelli","year":"2009","journal-title":"New Microbiol"},{"key":"10.1016\/j.vaccine.2021.04.014_b0085","first-page":"626","article-title":"Rapid increase in pertactin-deficient Bordetella pertussis isolates","volume":"20","author":"Lam","year":"2014","journal-title":"Australia. Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.014_b0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031985","article-title":"Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan","volume":"7","author":"Otsuka","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.04.014_b0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1128\/CVI.00717-13","article-title":"Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States","volume":"21","author":"Pawloski","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.04.014_b0100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijid.2014.08.002","article-title":"Pertactin-negative Bordetella pertussis strains in Canada: characterization of a dozen isolates based on a survey of 224 samples collected in different parts of the country over the last 20 years","volume":"28","author":"Tsang","year":"2014","journal-title":"Intl J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.014_b0105","doi-asserted-by":"crossref","unstructured":"Zeddeman A, van Gent M, Heuvelman CJ, van der Heide HG, Bart MJ, Advani A, et al. Investigations into the emergence or pertactin-deficient Bordetella pertussis isolates in six European countries 1996 to 2012. Euro Surveill 2014;19:pii=20881.","DOI":"10.2807\/1560-7917.ES2014.19.33.20881"},{"key":"10.1016\/j.vaccine.2021.04.014_b0110","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2014.09.068","article-title":"Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine","volume":"32","author":"Hegerle","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.014_b0115","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1016\/j.vaccine.2015.09.064","article-title":"Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model","volume":"33","author":"Safarchi","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.014_b0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/cid\/ciw632","article-title":"Clinical manifestations and molecular characterization of pertactin-deficient and pertactin-producing Bordetella pertussis in children, Philadelphia 2007\u20132014","volume":"64","author":"Vodzak","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.014_b0125","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1128\/iai.62.3.769-778.1994","article-title":"Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis","volume":"62","author":"Menozzi","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2021.04.014_b0130","doi-asserted-by":"crossref","first-page":"e01301","DOI":"10.1128\/genomeA.01301-14","article-title":"Complete genome sequences of Bordetella pertussis isolates B1917 and B1920 representing two predominant global lineages","volume":"2","author":"Bart","year":"2014","journal-title":"Genome Announc"},{"key":"10.1016\/j.vaccine.2021.04.014_b0135","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1128\/iai.41.3.1138-1143.1983","article-title":"Effect of heptakis (2,6-O-dimethyl) beta-cyclodextrin on the production of pertussis toxin by Bordetella pertussis","volume":"41","author":"Imaizumi","year":"1983","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2021.04.014_b0140","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/0076-6879(94)35161-9","article-title":"Use of conditionally counterselectable suicide vectors for allelic exchange","volume":"235","author":"Stibitz","year":"1994","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.vaccine.2021.04.014_b0145","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jmb.2005.05.071","article-title":"The periplasmic binding protein of a tripartite tricarboxylate transporter is involved in signal transduction","volume":"351","author":"Antoine","year":"2005","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2021.04.014_b0150","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.vaccine.2018.02.017","article-title":"Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3","volume":"36","author":"Debrie","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.014_b0155","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1016\/j.vaccine.2014.06.019","article-title":"Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice","volume":"32","author":"Feunou","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.014_b0160","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3389\/fmicb.2020.02108","article-title":"Acellular pertussis vaccines induce anti-pertactin bactericidal antibodies which drives the emergence of pertactin-negative strains","volume":"11","author":"Lesne","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2021.04.014_b0165","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1016\/j.vaccine.2009.07.074","article-title":"First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin","volume":"27","author":"Bouchez","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.014_b0170","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1128\/CVI.00367-12","article-title":"Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland","volume":"19","author":"Barkoff","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.04.014_b0175","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3201\/eid2511.190329","article-title":"Rare detection of Bordetella pertussis pertactin-deficient strains in Argentina","volume":"25","author":"Carriquiriborde","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.014_b0180","doi-asserted-by":"crossref","unstructured":"Barkoff AM, Mertsola J, Pierard D, Dalby T, Hoegh SV, Guillot S, et al. Pertactin-deficient Bordetella pertussis isolates: evidence of increased circulation in Europe, 1998 to 2015. Euro Surveill 2019;24:pii=1700832.","DOI":"10.2807\/1560-7917.ES.2019.24.7.1700832"},{"key":"10.1016\/j.vaccine.2021.04.014_b0185","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/cid\/ciu788","article-title":"Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage","volume":"60","author":"Martin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.014_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.epidem.2020.100388","article-title":"Emergence of pertactin-deficient pertussis strains in Australia can be explained by models of vaccine escape","volume":"31","author":"Jayasundara","year":"2020","journal-title":"Epidemics"},{"key":"10.1016\/j.vaccine.2021.04.014_b0195","doi-asserted-by":"crossref","first-page":"E340","DOI":"10.1111\/j.1469-0691.2012.03925.x","article-title":"Evolution of French Bordetella pertussis and Bordetella parapertussis isolates : increase of Bordetellae not expressing pertactin","volume":"18","author":"Hegerle","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2021.04.014_b0200","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3201\/1903.121475","article-title":"Virulence of pertactin-negative Bordetella pertussis isolates from infants","volume":"19","author":"Bodilis","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.014_b0205","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jinf.2015.11.004","article-title":"The relationship between Bordetella pertussis genotype and clinical severity in Australian children with pertussis","volume":"72","author":"Clarke","year":"2016","journal-title":"J Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21004497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21004497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:55:45Z","timestamp":1759402545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21004497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":41,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0264410X21004497"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.014","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Construction and evaluation of a pertactin-deficient live attenuated pertussis vaccine candidate BPZE1 derivative","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}